DB16335

GPTKB entity

Statements (43)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2020
gptkbp:ATCCode J05AB16
gptkbp:bioavailability low (IV only)
gptkbp:CASNumber 1809249-37-3
gptkbp:contraindication hypersensitivity to remdesivir
gptkbp:drugClass antiviral drug
gptkbp:eliminationHalfLife 1 hour (remdesivir), 25 hours (GS-441524)
gptkbp:excretion renal
gptkbp:hasDrugType small molecule
gptkbp:hasInChIKey RWWYLEGWBNMMLJ-YSOARWBDSA-N
gptkbp:hasMolecularFormula C27H35N6O8P
gptkbp:hasSMILES CC(C)[C@@H](NC(=O)[C@@H]1O[C@]([C@@H](O)[C@H](CO)O1)(C#N)O)P(=O)(O)OCC2=CN=CN2C3=CC=CC=C3
gptkbp:hasUNII 53J0A36V2L
https://www.w3.org/2000/01/rdf-schema#label DB16335
gptkbp:indication gptkb:COVID-19
gptkb:Ebola_virus_infection
gptkbp:legalStatus prescription only
patented
gptkbp:manufacturer gptkb:Gilead_Sciences
gptkbp:mechanismOfAction RNA polymerase inhibitor
gptkbp:metabolism hepatic
gptkbp:molecularWeight 602.6 g/mol
gptkbp:name gptkb:Remdesivir
gptkbp:pregnancyCategory Not assigned
gptkbp:PubChem_CID gptkb:DB16335
121304016
CHEMBL2016761
D11472
58191791
gptkbp:routeOfAdministration intravenous
gptkbp:sideEffect nausea
elevated liver enzymes
hypersensitivity
gptkbp:status FDA approved
EMA approved
gptkbp:synonym gptkb:GS-5734
gptkbp:target RNA-dependent RNA polymerase
gptkbp:bfsParent gptkb:Lumykras
gptkb:Sotorasib
gptkb:142217-69-4
gptkb:1369773-39-6
gptkbp:bfsLayer 7